The Anti-nuclear Antibody (ANA) testing market size is expected to reach USD 1.6 billion by 2032 at 11.3% CAGR during the forecast period 2023-2032. Antinuclear Antibody (ANA) Test detects antinuclear antibodies in the blood. The immune system makes antibodies to fight infections. Antinuclear antibodies attack on own tissues. It helps to recognize autoimmune diseases such as rheumatoid arthritis and lupus. The rise in technological advancements, higher adoption rate of new techniques, and growing concern of autoimmune diseases are driving the antinuclear antibody (ANA) testing market growth. Major industrial players are investing in research and development for the development of advanced products, which is another key growth factor for the market.
North America holds the prime position in Anti-nuclear Antibody (ANA) Testing market. U.S. hold the largest share and the European region is the second-largest and due to the higher growth rate in west European countries. The Asia-Pacific (APAC) is rapidly growing and significantly maintains a significant growth rate in the forecast period. The Middle East and Africa (ME&A) will show limited growth due to less awareness of devices and treatment. This regional development will boost the global growth rate of the market.
September 2023
Anti-nuclear Antibody (ANA) Testing Market has been segmented on the basis of type which comprise immunofluorescence (Primary or direct and Secondary or indirect), enzymelinked, immunosorbent assay (ELISA) (Direct ELISA, Indirect ELISA, Sandwich ELISA, Competition/Inhibition ELISA), and others.
On the basis of application, it segmented into Rheumatoid arthritis (Seropositive, Seronegative), Systemic lupus erythematosus (SLE) (Discoid lupus erythematosus, Subacute cutaneous lupus erythematosus, Neonatal lupus), Polymyositis, Scleroderma (localized scleroderma, systemic scleroderma), Sjögren's syndrome (Primary, secondary) , and others.
On the basis of end user, it segmented into Hospitals and clinics, research laboratories, and others.
Considering the global scenario of the market, North America is largest market for Anti-nuclear Antibody (ANA) Testing, in North America region US hold largest market share while European market is second largest, and especially the growth rate is higher in west European countries. On the other hand, Asia-Pacific (APAC) is fastest growing market and expected to grow significantly during the forecast period. Middle East and Africa (ME&A) is likely to have a limited growth in the market due to less awareness of devices and treatment.
Recent Development
In May 2022
The U.S. Food and Drug Administration (FDA) has cleared ZEUS Scientific's dIFine® digital immunofluorescence system* for use with ZEUS' ANA HEp-2 indirect fluorescent antibody (IFA) assay.
The FDA-cleared ZEUS dIFine® digital immunofluorescence system is the next generation in IFA imaging and pattern recognition designed to acquire, analyze, display and store digital images of ZEUS IFA HEp-2 cells. An automated digital scanner with intelligent software, ZEUS dIFine quickly delivers positive/negative results and has been programmed to suggest eight common ANA HEp-2 patterns (homogenous, speckled, centromere, nucleolar, nuclear dots, nuclear membrane, cytoplasmic (ribosomal and mitochondrial)). dIFine also instantly locates and identifies mitotic cells to assist in pattern identification. Quickly viewing and validating all negative samples with a single mouse click saves the user valuable time.
| Attribute/Metric | Details |
| Market Size 2022 | NA (USD Billion) |
| Market Size 2023 | NA (USD Billion) |
| Market Size 2032 | 1.6 (USD Billion) |
| Compound Annual Growth Rate (CAGR) | 11.3 % (2024- 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2022 |
| Market Forecast Period | 2023 - 2032 |
| Historical Data | 2019 - 2022 |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Abcam plc. (US), Alere (US), Antibodies Inc.(US), Bio-Rad Laboratories, Inc. (US), Erba Diagnostics (US), Indur Services, Inc. (US), MBL INTERNATIONAL (US), Merck KGaA (Germany), Trinity Biotech (Republic of Ireland) |
| Key Market Opportunities | Rising awareness about autoimmune diseases among healthcare professionals and patients |
| Key Market Drivers | Awareness of devices and treatment. |
Anti Nuclear Antibody Testing Market Highlights:
Frequently Asked Questions (FAQ) :
Anti-Nuclear Antibody Testing Market is projected to grow at a 11.20% CAGR between 2023-2032.
Anti-Nuclear Antibody Testing Market predicted to touch USD 1.6 billion by 2032.
North America is expected to dominate the Anti-Nuclear Antibody Testing Market.
Different end user industries of Anti-Nuclear Antibody Testing Market include research laboratories, hospital and clinics, and others.
Different strategies used by market players to create a dominance in the Anti-Nuclear Antibody Testing Market include mergers, acquisitions, collaborations, and product launches.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
| FEATURES | LICENCE TYPE | ||
|---|---|---|---|
| Single User | Multiuser Licence | Enterprise User | |
| Price | $ 4,950 | $ 5,950 | $ 7,250 |
| Maximum User Access Limit | 1 User | Upto 10 Users | Unrestricted Access Throughout The Organization. |
| Free Customization |  |
|
|
| Direct access to the Analyst | |
|
|
| Deliverable Format | |
|
|
 |
|
|
|
| Platform Access | |
|
|
| Discount on Your Next Purchase | 10% | 15% | 10% |
| Printable Versions | |
|
|
Research Analyst Level I
He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
